Has Jeffrey Loh-Doyle, MD received payments from drug or device companies?

Yes. Drug and device makers reported $307,856 in general payments to Jeffrey Loh-Doyle, MD across 531 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Loh-Doyle, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Loh-Doyle, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Loh-Doyle, MD

Urology · Los Angeles, CANPI 1477996833

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $196,401 of the $307,856 with a category attached, or 63.8%. Boston Scientific accounts for 93.0% of it on its own, with 10 other manufacturers making up the rest. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$307,856in general payments, 2019–2025

Across 531 payments — averaging $579.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$286K
Coloplast$16K
Uromedica, Incorporated$3K
Innovation Technologies Inc$2K
Teleflex LLC$193
Janssen Research & Development, LLC$85
plus $159 from 5 others

$49,542in research payments, 2019–2025

Across 16 payments — averaging $3096.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Coloplast$32K
Boston Scientific$18K

What the payments were for

Consulting fees$65,29021%
Speaking & faculty fees$196,40164%
Travel & lodging$30,20110%
Food & beverage$15,9645%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	472	$286,371
Coloplast	40	$16,499
Uromedica, Incorporated	1	$2,500
Innovation Technologies Inc	10	$2,049
Teleflex LLC	2	$193
Janssen Research & Development, LLC	1	$85
Antares Pharma, Inc.	1	$50
Baxter Healthcare	1	$43
Greenwich Biosciences, Inc.	1	$24
AbbVie	1	$23
Sagent Pharmaceuticals	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TACTRA$79,056
GENERAL ERECTILE DYSFUNCTION$59,741
AMS$28,846
AMS 700 CXR RTE KIT$21,828
AdVance XP$10,405
GENERAL - THERAPIES$5,121
AMS 800 Artificial Urinary Sphincter$4,507
TITAN$3,420
ProACT$2,500
Irrisept$1,881
ADVANCE$1,750
AMS 700$1,195
ZERO TIP$800
NEPHROMAX$800
Urovac Bladder Evacuator$800
PERCUTANEOUS TRACT KIT$800
Piranha$400
OPTIFLEX$400
AMS AMBICOR$302
AMBICOR$228

How this compares

$307,856 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.

See all urology providers in California →

Medicare billing

Part B allowed, 2024

$204,876

Medicare patients

515

Services billed

1,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	84	$61,505
GemtesaVibegron	17	$13,870
Tamsulosin Hcl	211	$3,083
Finasteride	128	$1,397
Oxybutynin Chloride ErOxybutynin Chloride	36	$902
Solifenacin Succinate	23	$858
Methenamine Hippurate	12	$582
Dutasteride	15	$483
Terazosin Hcl	12	$283
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip	11	$191
Oxybutynin Chloride	16	$123
Cephalexin	22	$115
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	23	$75
Meloxicam	16	$62

Paid to pharmacies, not to this prescriber.

Other urology in Los Angeles

Arie BelldegrunLos Angeles$1.8M
Mihir DesaiLos Angeles$1.5M
Stuart HoldenLos Angeles$1.1M
William AronsonLos Angeles$540K
Amir LebastchiLos Angeles$478K
Nazy ZomorodianLos Angeles$309K
Siamak DaneshmandLos Angeles$306K
Karim ChamieLos Angeles$291K
Brian ShuchLos Angeles$166K
Robert ReiterLos Angeles$145K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →